Slides
Page 1
Rafael Padilla CEO|Karin de Jong CFO31 July 20251H1 2025 Results
Page 2
The contents of this document, including all statements made therein, are based on estimates, assumptions and other information currently available to themanagement of Fagron.Certain statements in this presentation may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influencedby various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannotaccept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.This document, including all information contained therein, is not intended as, and may not be construed as, an offer or solicitation by Fagron for the purchase ordisposal of, trading or any transaction in any Fagron securities. Investors must not rely on this information for investment decisions and are solely responsible forforming their own investment decisions. The information provided in this document is intended for information purposes only and do not constitute a prospectus or anyother type of offering document pursuant to any applicable legislation.Disclaimer 2
Page 3
3Key highlightsRafael Padilla | CEO3
Page 4
Exceptional H1 2025 performance supported by all regions 4 Free cash flow* Total revenueRevenue organic growth CERREBITDANet debt ratio REBITDA margin €476.1m€429.3m11.3%12.8%€95.0m€84.6m20.0%19.7%€37.9m€45.4m1.5x1.5x H1 2025 H1 2024 Strong organic revenue growth at CER supported by all regions and segments30bps margin expansion YoY driven by operational excellence benefits and synergies from acquisitionsFree cash flow decreased by 16.5% YoY to €37.9m* due to temporary inventory build-up in Brazil$29 million one-off investment to expand Anazao’s Las Vegas 503B facility, beginning in Q4 2025 New market entries and consolidation through four acquisitions: Bella Corp (AUS), Uni-Chem & SB Trade (SRB) and Active Pharma (UK) Reiterate FY 2025 outlook*Adjusted for one-off capex and factoring
Page 5
EMEA: Diversified footprint, operational excellence and M&A drive performance 5 B&E performance shows solid demand underpinned by the benefits of our diversified footprint CS performance reflects favorable market dynamics which are expected to continue through the second half of the year Strong operational excellence focus with increased product availability and procurement savings Consolidated leading UK market position with acquisition of Active Pharma in the Essentials segment Entering the attractive Serbian B&E market with the acquisition of Uni-Chem and SB Trade +3.8%Organic revenue growth at CER21.8%REBITDA margin8Quality audits
Page 6
Latin America: Operational excellence driving strong performance 6 Sustained market leadership and underlying demand improving in Brazil Consulfarma, the largest industry fair globally took place in July 2025 Brands performance driven by innovative product launches and increased prescriber adoption Operational efficiencies and commercial focus support margin expansion Injeplast and Purifarmaacquisitions pending closure +16.1%Organic revenue growth at CER17.4%REBITDA margin1Quality audit
Page 7
North America: Strong underlying demand with quality a key competitive differentiator 7B&E performance driven by operational excellence and drug shortages CS continued its strong momentum benefitting from upsizing customers, new customer wins and drug shortages Phased transition progressing as planned at the new Anazaofacility One-off capex of $29m at Anazao’s Las Vegas facility to expand capacity; Wichita expansion progressing as planned Entered into the APAC region with the acquisition of Bella Corp in Australia +15.6%Organic revenue growth at CER19.5% 7Quality auditsREBITDA margin
Page 8
Quality focus remains a key strategic priority across the organization 8 35+Facilities to audit 16External audits 75+Regulatory bodies H1 2025 Global Quality KPIs Regulatory developments in the US present a compelling opportunity for differentiation Wichita:FDA acknowledges corrective actions adequately address its requirements, pending site visit Fagron Services Netherlands: cGMP inspection & license renewed Fagron Czech Republic: cGMP inspection & license renewed Multiple internal audits across all regions
Page 9
Supporting our growth strategy through organic investment and M&A 9 Expansion of Anazao facility in Las Vegas Further four acquisitions closed • Will include increased number of automated vial and pellet machines• Operational leverage as the facility will not require individual state pharmacy licenses Investment rationale: Capture rising demand, maintain highest quality standards and boost automation $29mInvestment $150mRevenue Capacity • Entry into the attractive APAC region and Serbian market •Bella Corp: Supplier of premium quality materials and equipment•Uni-Chem:Specializes in the import, sales, marketing, and distribution •SB Trade:Repackaging and relabeling of API’s and excipients•Active Pharma: A leader in Essentials providing API’s and excipients €13mCombined enterprise value Combined Financials:Revenue: Mid-to-high teensEBITDA margin: Below Group margin
Page 10
10Financial reviewKarin de Jong | CFO10
Page 11
H1 2025 financial highlights 11 Revenue growth seen across the board, partially offset by FX Gross margin improvement of 140bps YoY driven by the geographical sales mix and procurement savings Opex reflects costs to support volume growth in NA and integration of recent acquisitions REBITDA margin expansion of 30bps supported by operational excellence benefits globally and synergies from acquisitions Operating cash flow improved by 25.1% to €52.5m Net Debt to EBITDA ratio broadly stable at 1.5x versus 1.4x at end of FY 2024 429.3 476.1 H1 2024 H1 2025Revenue in €m+10.9%+11.3%Org. growth CER84.6 95.0 19.7%20.0%15.0%16.0%17.0%18.0%19.0%20.0%21.0%22.0%23.0% 20.0 45.0 70.0 95.0H1 2024 H1 2025REBITDA in €mREBITDA margin+12.3%
Page 12
H1 2025 Revenue bridge and P&L statement 12 ΔH1 2024H1 2025Profit & loss account (€m)10.9%429.3 476.1Net revenue13.4%264.4299.9Gross margin14.1%178.5203.6Operating expenses-6.3%1.41.3Share-based payments and LTI12.3%84.695.0EBITDA before non-recurrent result190.6%-1.3 1.1Non-recurrent result15.4%83.496.2EBITDA16.5%19.723.0Depreciation and amortization15.0%63.673.2EBIT-18.6%-11.9-14.2Financial result14.2%51.759.1Profit before income tax-20.0%-11.1-13.3Taxes12.6%40.745.8Net profit12.7%0.550.62Net profit per share (€)72,986,90572,952,685Average number of outstanding shares476.16.213.828.613.1-15.0429.3350.0370.0390.0410.0430.0450.0470.0490.0 H1 2024 EMEA LatAm NA Acquisitions FX H1 2025 in €m
Page 13
EMEA: Growth across all segments as strategic actions bear fruit 13 Topline growth of 10.3% YoY reflects a solid organic performance across all segments and contribution from M&A Price volume dynamics driven by balanced regional exposure and competitive positioning REBITDA margin expansion supported by the execution of our strategic priorities and focus on operational excellence Uni-Chem and SB Trade in Serbia and Active Pharma in the UK closed in July 81.7 92.8 25.0 27.6 53.5 56.5 H1 2024 H1 2025EssentialsBrandsCompounding+10.3%34.0 38.5 21.2%21.8%10.0%15.0%20.0%25.0%30.0%35.0% 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0H1 2024 H1 2025REBITDA in €mREBITDA margin+13.1%+3.8%Org. growth CER RevenueProfitability160.3176.9
Page 14
Latin America: Strong revenue growth partly offset by FX volatility 1455.0 53.7 28.7 31.3 2.2 1.9 0.040.080.0120.0H1 2024 H1 2025EssentialsBrandsCompounding+1.1%14.9 15.1 17.3%17.4%10.0%15.0%20.0%25.0%30.0%35.0% 10.0 11.0 12.0 13.0 14.0 15.0 16.0 17.0 18.0H1 2024 H1 2025REBITDA in €mREBITDA margin+1.5%+16.1%Org. growth CER86.086.9Topline growth of 1.1% YoY reflects strong growth in Brands & Essentials partially offset by negative FX impact Brands revenue proportion increased to 36.0% of LatAm revenue, an increase of 260 basis points YoY Positive price and volume growth supported by increasing underlying demand REBITDA margin increased by 10bps supported by operational excellence initiatives Revenue Profitability
Page 15
North America: Strong revenue momentum with stable profitability 15 34.4 42.1 11.9 10.8 136.8 159.4 0.040.080.0120.0160.0200.0240.0H1 2024 H1 2025EssentialsBrandsCompounding+16.0%35.7 41.4 19.5%19.5%10.0%15.0%20.0%25.0%30.0%35.0% 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0H1 2024 H1 2025REBITDA in €mREBITDA margin+16.0%+15.6%Org. growth CER183.1212.4Revenue growth of 16.0% YoY reflecting a strong performance by CS and Essentials with a small FX headwind Strong volume growth reflects strong underlying demand and market share gains REBITDA margin stable at 19.5%, as improved operational performance was offset by facilitation of strong volume growth and overlapping costs at AnazaoTampa Acquisition of Bella Corp in Australia closed at end of June RevenueProfitability
Page 16
Cash flow performance remains robust 16 Operating working capital as percentage of annualized revenue increased by 150bps YoY to 13.8% driven by higher temporary inventories in BrazilOperating cashflow increased by 25.1% to €52.5mMaintenance capex was 3.1% of revenue excluding one-off capexFree cash flow conversion of 39.9% adjusted for one-off capexH1 2024H1 2025€m83.496.2EBITDA(31.2)(34.3)Changes to working capital*(10.3)(9.4)Income tax paid41.952.5Cash flow from operating activities41.951.5 51.552.541.912.80.93.20.010.020.030.040.050.060.0H1 2024 EBITDA Changes to workingcapitalIncome tax paid H1 2025 Cash flow from operating activities development (€m) *Including impact of non-cash item
Page 17
Robust balance sheet with flat net debt to EBITDA ratio 17 Net financial debt increased by €49.9m to €320.6m Net Debt to EBITDA ratio stable YoY at 1.5x at end of H1 2025 Ample headroom to pursue opportunities, with leverage well below the internal threshold of 2.8x Net debt evolution218.2216.6 216.6261.7276.9295.9301.3301.3320.6270.745.115.219.017.219.352.51.611.9On 31 Dec 2024 Operational cashflowCapital increases Acquisitions Capital expenditure Dividends paid Net interests FX IFRS 16 On 30 Jun 2025€m
Page 18
FY 2025 outlook reaffirmed 18Guidance assumes no significant changes in market conditions. Also excludes signed acquisitions that are not closed* Excludes one-off capex projects Mid- to high-single digit organic growth at CERRevenue~3.5% of revenue* Capex Slight increase in profitability y-o-yREBITDA margin
Page 19
19ConclusionRafael Padilla | CEO19
Page 20
Investment proposition 20 Together we create the future of personalizing medicine Solid execution capabilitiesHighest quality will drive long-term successStrong operational and commercial strategies Optimized capital utilizationRight people, values and passion Only true global player
Page 21
Questions 21